Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
VRK1
REST API REST API
Homo sapiens
VRK1 is differentially expressed in 283 experiments: 90 organism parts: bone marrow, liver, ... (88 more);, 207 disease states: normal, colon carcinoma, ... (205 more);, 100 cell types 380 cell lines 32 compound treatments and 68 other conditions.
Orthologs VRK1 (Gallus gallus)   YCK3 (Saccharomyces cerevisiae)   YCK2 (Saccharomyces cerevisiae)   Vrk1 (Rattus norvegicus)   YCK1 (Saccharomyces cerevisiae)   vrk1 (Danio rerio)   Vrk1 (Mus musculus)   VRK1 (Bos taurus)   ENSCING00000006395 (Ciona intestinalis)   CG8878 (Drosophila melanogaster)   ball (Drosophila melanogaster)   vrk1 (Xenopus laevis)   VRK1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, cytoplasm, ATP binding, nucleus, nucleotide binding, protein serine/threonine kinase activity, protein kinase activity, nucleolus, protein autophosphorylation, protein phosphorylation
InterPro Term Prot_kinase_cat_dom, Ser/Thr_kinase_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q99986
Gene-Disease Assocation PONTOCEREBELLAR HYPOPLASIA, TYPE 1; PCH1
Search EB-eye ENSG00000100749
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-AFMX-5, E-MEXP-1251, E-MTAB-24, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (38 experiments)

Factor Value U/D Experiments
HL-60
1
3
E-MTAB-37, E-GEOD-24147, E-GEOD-5258, E-GEOD-96
Jurkat
2
E-GEOD-1880, E-MTAB-62
HT1080
2
E-MTAB-37, E-GEOD-20089
MCF-7
2
E-GEOD-19639, E-GEOD-20081
MOLT4
2
E-MTAB-37, E-MTAB-62
PC3
2
E-MEXP-2034, E-GEOD-5258
374 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-3920, E-GEOD-4219, E-GEOD-20677, E-GEOD-13987, ... (44 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
type II helper T cell
1
E-GEOD-3982
neurosphere cell
1
E-MEXP-551
94 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (59 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-62, E-GEOD-3726, E-MTAB-57, E-MTAB-37
glioblastoma
3
E-GEOD-6014, E-MTAB-37, E-MTAB-62
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
dermatomyositis
2
E-MTAB-62, E-GEOD-5370
acute promyelocytic leukemia
1
2
E-GEOD-995, E-GEOD-96, E-MTAB-62
prostate carcinoma
1
2
E-GEOD-96, E-MEXP-2034, E-MTAB-37
201 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-GEOD-6462, E-MEXP-2590, ... (23 experiments)

Factor Value U/D Experiments
dimethyl sulfoxide
2
E-GEOD-5824, E-GEOD-6932
none
4
5
E-GEOD-5824, E-GEOD-20719, E-MEXP-1601, E-GEOD-412, E-TABM-782, ... (9 experiments)
platelet-derived growth factor
1
E-GEOD-1923
control - keratinocyte growth factor
1
E-GEOD-7216
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
26 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
73 years
1
E-GEOD-4922


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-MTAB-37, E-TABM-176, E-MEXP-1251, E-GEOD-1563, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MEXP-958, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-TABM-26, E-TABM-147, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-17385, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-MEXP-1437, E-GEOD-17476, E-TABM-868, E-GEOD-18005, E-TABM-601, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-20504, E-GEOD-22278, E-GEOD-19018, ... (11 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-TABM-15, E-GEOD-16363, ... (29 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-6802

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-4600, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815, ... (7 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.428 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM